Bristol Working Capital

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>BM</div>
BMY -- USA Stock  

Report: 6th of August 2020  

Bristol Myers working capital fundamental analysis lookup allows you to check this and other indicators for Bristol Myers Squibb or any other equity instrument. You can also select from a set of available indicators by clicking on the link to the right. Please note, not all equities are covered by this module due to inconsistencies in global equity categorizations. Please continue to Equity Screeners to view more equity screening tools

Search Working Capital

 
Refresh
Bristol Myers Invested Capital is fairly stable at the moment as compared to the past year. Bristol Myers reported Invested Capital of 59.57 Billion in 2019. Return on Invested Capital is likely to grow to 0.18 in 2020, whereas Working Capital is likely to drop slightly above 9.3 B in 2020.

Bristol Working Capital Analysis

Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

  Bristol Myers Total Debt

Working Capital 
 = 
Current Assets 
Current Liabilities 
More About Working Capital | All Equity Analysis

Current Bristol Myers Squibb Working Capital

2.4 B

Bristol Working Capital Over Time Pattern

 Bristol Myers Working Capital 
      Timeline 

About Working Capital

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
Compare to competition

Bristol Myers Working Capital Related Assessment

  Capital Expenditure

Bristol Myers Squibb has Working Capital of 2.4 B. This is much higher than that of the Healthcare sector and significantly higher than that of Drug Manufacturers?General industry. The working capital for all United States stocks is 62.23% lower than that of the firm.

Did you try this?

Run Portfolio Diagnostics Now

   

Portfolio Diagnostics

Use generated alerts and portfolio events aggregator to diagnose current holdings
All  Next Launch Module

Bristol MyersCurrent Valuation Drivers

2014201520162017201820192020 (projected)
Revenue Per Employee635.16 K662.4 K774.96 K876.62 K968.28 K871.5 K774.9 K
Average Assets33.53 B32.27 B33.04 B33.47 B33.61 B69.34 B57.53 B
Earnings before Tax2.36 B2.01 B5.87 B5.16 B5.94 B4.95 B4.63 B
Average Equity15.2 B15 B15.27 B13.91 B13.2 B25.13 B22.34 B
Enterprise Value100.73 B118.06 B101.06 B104.1 B86.74 B99.05 B100.45 B
Free Cash Flow2.62 B1.28 B1.84 B4.22 B4.99 B7.23 B6.09 B
Invested Capital18.77 B19.73 B19.08 B18.46 B17.14 B59.57 B64.27 B
Tangible Asset Value24.97 B23.45 B25.45 B25.48 B27.36 B43.49 B38.07 B
Working Capital6.15 B2.4 B4.86 B5.29 B7.06 B11.05 B9.3 B
Interest Coverage12.7610.2727.7218.4327.979.019.25
Calculated Tax Rate14.7821.4723.881.017.1130.4526.35
PPandE Turnover3.313.533.754.134.164.54.64
Receivables Turnover7.396.045.44.574.324.015.96
Inventory Turnover2.572.814.025.045.552.943.12
Operating Margin16.3211.4123.8317.3922.6922.6223.88
Return on Investment11.228.6621.1216.9624.929.8815.4
Cash Flow Per Share1.91.11.713.253.663.583.03
Revenue to Assets0.420.470.520.580.620.20.21
Quick Ratio1.150.931.171.241.341.261.13
Book Value per Share8.958.559.687.178.631.6734.17
Current Ratio1.521.731.31.551.661.61.54
Debt to Equity Ratio1.541.261.211.851.491.521.57
Dividend Yield0.0330.0250.0220.020.0310.0260.0269
EBITDA Margin0.140.220.180.320.290.260.25

Bristol Fundamentals

About Bristol Myers Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way. Please read more on our fundamental analysis page.
 2017 2018 2019 2020 (projected)
Receivables5.09 B5.35 B7.68 B8.29 B
Inventories1.17 B1.2 B4.29 B4.63 B


 
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page